Financial Quality Control of In-Patient Chemotherapy in Germany: Are Additional Payments Cost-Covering for Pharmaco-Oncological Expenses?

Breast care

Volker R. Jacobs¹  Peter Mallmann¹ 

[1] Frauenklinik (OB/GYN), University Clinic of Cologne, Cologne, Germany

关键词: In-patient chemotherapy;    Hospital economics;    Cost-revenue calculation;    German diagnose-related groups (G-DRGs);    Additional in-patient payment;   

DOI  :  10.1159/000327354

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Cost-covering in-patient care is increasingly important for hospital providers in Germany, especially with regard to expensive oncological pharmaceuticals. Additional payments (Zusatzentgelte; ZE) on top of flat rate diagnose-related group (DRG) reimbursement can be claimed by hospitals for in-patient use of selected medications. To verify cost coverage of in-patient chemotherapies, the costs of medication were compared to their revenues.

【 授权许可】

Unknown